期刊
BLOOD PRESSURE
卷 18, 期 6, 页码 304-307出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/08037050903416436
关键词
Prehypertension; cardiovascular risk; pharmacotherapy; cost-effectiveness
People with prehypertension undoubtedly have an increased risk of cardiovascular and other complications. The vast majority have low absolute risk and whether drug treatment would be beneficial is uncertain. While pharmacotherapy has attractions from a public health prospective, clinicians and crucially those with prehypertension require robust evidence that drug treatment will lead to short-term as well as long-term gains. Any changes in recommendations should await adequately powered outcome studies, which provide solid evidence of the magnitude of absolute risk reduction in treating prehypertension and assessment of the cost-effectiveness.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据